1 Life of Fund (LOF) if performance is less than 10 years. Fund inception date: 11/17/1986. 2 This expense ratio is from the most recent prospectus and generally is based on amounts incurred during ...

Good morning, everyone. My name is C.J. Muse, semiconductor equipment analyst here with Cantor Fitzgerald. Welcome to Cantor Global Technology and Industrial Growth Conference. Very pleased to have ...

Good morning, ladies and gentlemen, and welcome to the Altius Q4 and Year-End 2025 Financial Results Conference Call and Webcast. [Operator Instructions] Also note that this call is being recorded on ...

All right. Thank you, and welcome to Sprout Social's discussion of our System of Record and Action AI strategy at the company. My name is Alex Kurtz, Head of IR and Corp Dev here at Sprout Social. Our ...

Sabadra, and I cover information services companies at RBC Capital Markets. We are really excited to host Chris, CEO of TransUnion; and Todd, CFO of TransUnion. Thanks again for giving us this ...

Hello again, everyone. My name is Etzer Darout, one of the senior biotech analysts at Barclays. My pleasure to welcome Xencor to our fireside chat. With us today, we have Bassil Dahiyat, President and ...

Stagwell Inc. demonstrates operational momentum, with revenue and net revenue growth driven by digital transformation and marketing services. STGW stock trades at a deep discount, with a forward P/E ...

All right. Great. Thank you, everybody, for joining Day 3 of the Leerink Global Healthcare Conference. I'm joined by Elanco's CFO, Bob VanHimbergen; Head of the U.S. business, Bobby Modi. We've got ...

All right, guys. Why don't we get the ball rolling just to keep things on time. Really happy to have Affirm here with us. Affirm is a name that we've been covering now for really just a couple of ...

All right. Good morning, everyone, and welcome to the UBS Global Consumer and Retail Conference here in New York City. My name is Peter Grom. I'm the U.S. consumer staples analyst here at UBS, and we ...

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Dorel Industries' Fourth Quarter 2025 Results Conference Call. [Operator Instructions] Before turning the meeting over to ...

Hello, everyone. My name is Etzer Darout, the senior biotech analyst at Barclays. It's my pleasure to have Iovance Therapeutics for our next fireside chat. With me today, I have Brian Gastman, ...